Preliminary results from several clinical trials testing carfilzomib (Kyprolis) for the treat­ment of multiple myeloma will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.

Carfilzomib, a proteasome inhibitor, is under devel­op­ment as a treat­ment for re­lapsed or refractory multiple myeloma. It is cur­rently in Phase 2 of clinical testing, which means that its safety and efficacy are being studied.

The ASH presenters will examine the effects of car­filz­o­mib in patients who have pre­vi­ously been treated with Velcade (bor­tez­o­mib); …

On Monday, Onyx Pharmaceuticals agreed to purchase Proteolix, the developer of the cancer drug carfilzomib (Kyprolis), for $276 million. Carfilzomib, which is Proteolix’s leading cancer drug, has dem­onstrated significant tumor-reduction activity in Phase 1 trials of patients with re­lapsed multiple myeloma.

Similar to Velcade (bor­tez­o­mib), car­filz­o­mib is a proteasome inhibitor that blocks the activity of these protein-destroying enzymes and induces cancer cell death. Carfilzomib is cur­rently undergoing Phase 2 trials on patients with re­lapsed multiple myeloma, for which data will be reported in late 2010. Phase 3 trials combining car­filz­o­mib with

Preliminary results from an ongoing Phase 1 clinical trial indicate that carfilzomib (Kyprolis), a new proteasome inhibitor, has significant thera­peutic results in patients with re­lapsed myeloma. The Multiple Myeloma Research Consortium (MMRC) reported the results at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, which was held in Berlin from September 20 to 24.

Carfilzomib selectively induces cell death in cancer cells by blocking the activity of proteasomes, which are enzymes that break down proteins. Carfilzomib is similar to Velcade (bor­tez­o­mib), the first proteasome inhibitor approved for multiple myeloma treat­ment. However, car­filz­o­mib …

Description:

Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies …

A num­ber of new drugs are on the horizon for re­lapsed and re­frac­tory patients, as discussed by physicians at the 2009 Inter­na­tional Myeloma Workshop (IMW). The dis­cus­sion covered drugs in all stages of devel­op­ment, from those still undergoing initial lab testing to ones already in inter­na­tional clin­i­cal trials.

Overall re­spon­siveness to treat­ment has im­proved dramatically with the recent in­tro­duc­tion of more potent agents such as Revlimid (lena­lido­mide) and Velcade (bor­tez­o­mib). Doctors are now testing com­bi­na­tions of these two drugs with newer pharma­ceu­ticals. Of the two, Velcade has been …

Carfilzomib, a new drug similar to Velcade (bor­tez­o­mib), has been shown to be 18 per­cent to 54 per­cent effective against multiple myeloma in re­lapsed and refractory patients, depending on the level of prior treat­ment.

Carfilzomib ther­apy has pre­vi­ously been shown to result in greater than 80 per­cent proteasome inhibition. Furthermore, car­filz­o­mib in comparison to current treat­ments presents a reduction in the occurrence of periph­eral neu­rop­athy, a painful side effect that causes pain and numbness in the hands and feet. A pre­vi­ous article discusses how car­filz­o­mib uses proteasome inhibition to stop …

Carfilzomib, a new drug similar to Velcade (bor­tez­o­mib), has been shown to be effective against multiple myeloma in re­lapsed and refractory patients.

Like Velcade, car­filz­o­mib (also called PR-171) is a proteasome inhibitor that blocks the activity of proteasomes, cellular complexes that break down proteins.  Without proteasome activity, it is believed that cells self-induce death (apoptosis), thereby inhibiting tumor growth.

A Phase I study shows that car­filz­o­mib ther­apy results in greater than 80% proteasome inhibition.  Two ongoing Phase II studies have dem­onstrated complete or partial positive responses in 18% to 54% of patients, depending …